Marksans Pharma Overview

  • Year Founded
  • 1992

Year Founded

  • Status
  • Public

  • Employees
  • 852

Employees

  • Stock Symbol
  • MARKSANS

Stock Symbol

  • Investments
  • 8

  • Share Price
  • $2.26
  • (As of Friday Closing)

Marksans Pharma General Information

Description

Marksans Pharma Ltd is a pharmaceutical company. The company is engaged in the research, manufacturing, and marketing of pharmaceutical formulations. It manufactures analgesics, gastroenterology, anti-diabetic, cardiovascular, pain management, gynecology, gastrointestinal and oncologic drugs as well as antibiotics and antiallergic medications. It has a market presence with the majority of the revenue generated from the United States and North America, followed by Europe and the UK, Australia and New Zealand, India, and the Rest of the World.

Contact Information

Formerly Known As
Glenmark Laboratories Ltd.
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Drug Discovery
Stock Exchange
NSE
Corporate Office
  • 11th Floor, Grandeur
  • Veera Desai Extension Road, Oshiwara, Andheri West
  • Mumbai, Maharashtra 400053
  • India
+91 022 0000 0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Marksans Pharma Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.26 $2.30 $1.17 - $2.36 $1.03B 447M 2.54M $0.08

Marksans Pharma Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2024 31-Mar-2024 FY 2023 31-Mar-2023 FY 2022 31-Mar-2022
EV 748,834 748,834 355,650 209,340
Revenue 263,017 263,017 230,659 198,654
EBITDA 61,484 61,484 49,644 39,151
Net Income 37,893 37,893 33,165 24,772
Total Assets 321,482 321,482 266,792 216,291
Total Debt 29,266 29,266 14,975 14,609
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Marksans Pharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Marksans Pharma‘s full profile, request access.

Request a free trial

Marksans Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Marksans Pharma Ltd is a pharmaceutical company. The company is engaged in the research, manufacturing, and marketing of
Drug Discovery
Mumbai, India
852 As of 2023
0000

000000

rehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excep
000000000000000
Mumbai, India
00 As of 0000
00.000
0&0

000000

m, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo conse
000000000000000
Bangalore, India
0000 As of 0000
000.00
000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Marksans Pharma Competitors (16)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Novartis India Corporate Backed or Acquired Mumbai, India 00 00.000 0&0
Strides Pharma Science Corporation Bangalore, India 0000 000.00 000000000 000.00
Torrent Pharmaceuticals Corporation Ahmedabad, India 00000 0000 0000
Novartis Corporation Basel, Switzerland 00000 00.00 000000000 00.00
Dr. Reddy's Laboratories Corporation Hyderabad, India 00000 00000 000000 - 000 00000
You’re viewing 5 of 16 competitors. Get the full list »

Marksans Pharma Patents

Marksans Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220079894-A1 Stable pharmaceutical compositions Pending 11-Sep-2020 0000000000 0

Marksans Pharma Board Members (3)

Name Representing Role Since
0000 00000000 Marksans Pharma Founder, Chairman & Managing Director 000 0000
0000000000 0000000 Marksans Pharma Board Member 000 0000
00000000 0000000 Marksans Pharma Board Member 000 0000
To view Marksans Pharma’s complete board members history, request access »

Marksans Pharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Marksans Pharma Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Marksans Pharma‘s full profile, request access.

Request a free trial

Marksans Pharma Investments & Acquisitions (8)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Teva pharm India (manufacturing Unit) 19-Apr-2023 000000000 Buildings and Property 0000 0000
Tevapharm (Pharmaceutical Formulations Business) 18-Apr-2023 0000000000 00.00 Pharmaceuticals 0000 0000
Access Healthcare for Medical Products 06-Jun-2022 0000000000 00.000 Media and Information Services (B2B) 0000 0000
Time-Cap Labs 30-Jun-2015 0000000000 0000 Pharmaceuticals 0000 0000
Relonchem 28-Aug-2008 Merger/Acquisition 000.00 Pharmaceuticals 0000 0000
You’re viewing 5 of 8 investments and acquisitions. Get the full list »

Marksans Pharma Subsidiaries (5)

Company Name Industry Location Founded
Nova Pharmaceuticals Australasia Drug Discovery Australia 2003
Relonchem Pharmaceuticals Widnes, United Kingdom 0000
Time-Cap Labs Pharmaceuticals Farmingdale, NY 0000
Bell's Healthcare Pharmaceuticals Widnes, United Kingdom 0000
Access Healthcare for Medical Products Media and Information Services (B2B) Dubai, United Arab Emirates
To view Marksans Pharma’s complete subsidiaries history, request access »

Marksans Pharma ESG

Risk Overview

Risk Rating

Updated March, 05, 2024

38.16 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.00

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,216

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 921

Rank

00.00

Percentile

Pharmaceuticals

Subindustry

00 of 452

Rank

00.00

Percentile

To view Marksans Pharma’s complete esg history, request access »

Marksans Pharma Exits (1)

Company Name Exit Date Exit Type Exit Size Status Buyers
Hale Group 18-Jan-2008 000000000000000000 Completed
  • 00000000 000000
To view Marksans Pharma’s complete exits history, request access »

Marksans Pharma FAQs

  • When was Marksans Pharma founded?

    Marksans Pharma was founded in 1992.

  • Where is Marksans Pharma headquartered?

    Marksans Pharma is headquartered in Mumbai, India.

  • What is the size of Marksans Pharma?

    Marksans Pharma has 852 total employees.

  • What industry is Marksans Pharma in?

    Marksans Pharma’s primary industry is Drug Discovery.

  • Is Marksans Pharma a private or public company?

    Marksans Pharma is a Public company.

  • What is Marksans Pharma’s stock symbol?

    The ticker symbol for Marksans Pharma is MARKSANS.

  • What is the current stock price of Marksans Pharma?

    As of 12-Jul-2024 the stock price of Marksans Pharma is $2.26.

  • What is the current market cap of Marksans Pharma?

    The current market capitalization of Marksans Pharma is $1.03B.

  • What is Marksans Pharma’s current revenue?

    The trailing twelve month revenue for Marksans Pharma is $263M.

  • Who are Marksans Pharma’s competitors?

    Novartis India, Strides Pharma Science, Torrent Pharmaceuticals, Novartis, and Dr. Reddy's Laboratories are some of the 16 competitors of Marksans Pharma.

  • What is Marksans Pharma’s annual earnings per share (EPS)?

    Marksans Pharma’s EPS for 12 months was $0.08.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »